ArticleFrontiers in oncology2026

Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab.

David Gandara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.